Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation

What Was Tested

In this not phased trial, researchers set out to test Terlipressin for low blood pressure and orthostatic hypotension.

Prospective double blind randomized controlled trial.

It had two arms (groups): Placebo (normal saline) + Dopamine (placebo comparator) and Terlipressin + Dopamine (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 150 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients with end-stage renal disease aged 18 years or above.

The full record lists 1 inclusion and 6 exclusion criteria; among the exclusions: simultaneous multiple organ transplantation; known allergy to study medication; known pregnancy status.

How the Study Was Run

The set-up was randomized, parallel-group and quadruple-blind.

The low blood pressure and orthostatic hypotension participants were allocated by chance, so the Terlipressin group and the comparison group should start out alike.

Groups ran in parallel: each of the low blood pressure and orthostatic hypotension participants stayed in one arm throughout.

Neither the low blood pressure and orthostatic hypotension participants nor the staff measuring them knew who was on Terlipressin, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-03-06 with completion listed for 2026-06-15.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Delayed graft function (DGF) (time frame: Within 7 days after kidney transplantation).

It also tracked 5 secondary outcomes, for example Post-reperfusion dopamine requirement, Area under the curve for MAP below 100 mmHg after graft reperfusion, Early postoperative renal function (POD7), Serum creatinine after kidney transplantation at 3 months and 1 year and Estimated glomerular filtration rate (eGFR) after kidney transplantation at 3 months and 1 year.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Terlipressin in 150 people with low blood pressure and orthostatic hypotension.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Terlipressin compound page, Low blood pressure and orthostatic hypotension research.